Expression of CD28, FAS, PD1, and CTLA4 molecules in the blood of women with triple‐negative breast cancer

Background Locally advanced triple‐negative breast cancer (TNBC) represents a public health problem in Brazil. Its standard treatment consists of neoadjuvant chemotherapy (NAC). Methods This was a longitudinal study with follow‐up performed between the years 2015 and 2017. Thirty women with locally...

Full description

Saved in:
Bibliographic Details
Published in:Journal of surgical oncology 2024-09, Vol.130 (4), p.681-690
Main Authors: Salgado, Marcelo Ramos Tejo, Sobral, Denise Viana, Martins, Mario R., Salgado, Eduardo Forte M. T., Salgado, Amanda Forte M. T., Silva, Kamylla Ramos da, Soares, Fernando Augusto, Torres, Leuridan C.
Format: Article
Language:English
Subjects:
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Biomarkers, Tumor - blood
Breast cancer
Case-Control Studies
CD28 Antigens - blood
Chemotherapy
CTLA-4 Antigen - blood
fas Receptor - blood
Female
Follow-Up Studies
Humans
immune system
Longitudinal Studies
Lymphocytes
Middle Aged
Neoadjuvant Therapy
Prognosis
Programmed Cell Death 1 Receptor
T lymphocytes
triple negative breast neoplasms
Triple Negative Breast Neoplasms - blood
Triple Negative Breast Neoplasms - drug therapy
Triple Negative Breast Neoplasms - pathology
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Locally advanced triple‐negative breast cancer (TNBC) represents a public health problem in Brazil. Its standard treatment consists of neoadjuvant chemotherapy (NAC). Methods This was a longitudinal study with follow‐up performed between the years 2015 and 2017. Thirty women with locally advanced TNBC submitted to NAC, and 30 healthy were included. Peripheral blood samples were collected before NAC (Pre‐NAC) and after NAC (Post‐NAC). Results Patients with TNBC had elevated levels of CD28+ T, FAS+ T, CTLA4+ T, PD1+ T, CD28+CD4+ T, PD1+CD4+ T and CD8+ T and PD1+ CD8+ T cells compared to controls (p 
ISSN:0022-4790
1096-9098
1096-9098
DOI:10.1002/jso.27725